Mesoblast (MESO) Free Cash Flow (2014 - 2023)
Mesoblast (MESO) posted Free Cash Flow of -$16.5 million for Q2 2023, down 1.49% sequentially from -$16.2 million in Q1 2023, and down 18.7% YoY from -$20.3 million in Q2 2022.
Analysis
Mesoblast (MESO) Free Cash Flow (2014 - 2023) Analysis & Trends
Mesoblast has reported Free Cash Flow for 8 years, with the latest figure at -$16.5 million in Q2 2023.
- Quarterly Free Cash Flow fell 18.7% year-over-year to -$16.5 million in Q2 2023, while the trailing twelve-month figure through Dec 2024 was -$16.5 million (up 66.48% YoY) and the FY2025 annual result came in at -$50.7 million, down 4.0% from the prior year.
- Free Cash Flow fell to -$16.5 million in Q2 2023 per MESO's latest filing, from -$16.2 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$1.3 million in Q4 2019 and troughed at -$30.6 million in Q4 2020.
- A 5-year average of -$17.9 million and a median of -$17.3 million in 2021 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2020 and 2021: Free Cash Flow plunged 2199.25% in 2020, then surged 40.42% in 2021.
- Over 5 years, Free Cash Flow stood at -$1.3 million in 2019, then slumped by 2199.25% to -$30.6 million in 2020, then surged by 40.42% to -$18.2 million in 2021, then climbed by 9.69% to -$16.5 million in 2022, then decreased by 0.23% to -$16.5 million in 2023.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$16.5 million, -$16.2 million, and -$16.5 million for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 110.05 Mn |
| Mar 31, 2023 | -77.73 Mn |
| Dec 31, 2022 | 16.45 Mn |
| Sep 30, 2022 | 14.29 Mn |
| Jun 30, 2022 | -13.89 Mn |
| Mar 31, 2022 | -15.52 Mn |
| Dec 31, 2021 | -18.22 Mn |
| Sep 30, 2021 | 18.20 Mn |
| Jun 30, 2021 | -18.92 Mn |
| Mar 31, 2021 | -24.47 Mn |
| Dec 31, 2020 | -30.58 Mn |
| Sep 30, 2020 | -28.17 Mn |
| Mar 31, 2020 | -36.78 Mn |
| Dec 31, 2019 | -16.89 Mn |
| Sep 30, 2019 | -15.56 Mn |
| Mar 31, 2019 | -21.19 Mn |
| Dec 31, 2018 | -1.96 Mn |
| Sep 30, 2018 | -19.54 Mn |
| Jun 30, 2018 | -20.19 Mn |
| Mar 31, 2018 | -19.60 Mn |